Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age

Journal of the Pediatric Infectious Diseases Society

Volumn 4, Issue 4, 2015, Pages e76-e83

  Nachman, Sharon ^a   Alvero, Carmelita ^b   Acosta, Edward P ^c   Teppler, Hedy ^d   Homony, Brenda ^d   Graham, Bobbie ^e   Fenton, Terence ^b   Xu, Xia ^d   Rizk, Matthew L ^d   Spector, Stephen A ^f   Frenkel, Lisa M ^g   Worrell, Carol ^h   Handelsman, Edward ⁱ   Wiznia, Andrew ^j  

^a STONY BROOK UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SEATTLE CHILDREN S HOSPITAL   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j JACOBI MEDICAL CENTER   (United States)

more..

Author keywords

Pediatric HIV; Raltegravir; Treatment

Indexed keywords

INTEGRASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; INFANT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOTHER TO CHILD VIRUS TRANSMISSION; MULTICENTER STUDY; NEWBORN; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; SENSITIVITY ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS TRANSMISSION; CLINICAL TRIAL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ADMINISTRATION, ORAL; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; RALTEGRAVIR POTASSIUM;

EID: 85006213867     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piu146     Document Type: Article

References (11)

1. Nachman S, Zheng N, Acosta EP, et al. pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis 2014; 58:413-22.
2. National Institutes of Health Grading tables. http://rsc.tech-res.com/safetyandpharmacovigilance/gradingtables.aspx. Accessed August 30, 2009.
3. Long MC, Bennetto-Hood C, Acosta EP. A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 867:165-71.
4. Merschman SA, Vallano PT, Wenning LA, et al. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLCMS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 857:15-24.
5. Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11:907-15.
6. Rizk ML, Hang Y, Luo WL, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother 2012; 56:3101-6.
7. Rizk ML, Du L, Wenning L, et al. Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age. ICAAC 2014, September 5-9, 2014. Washington, DC. Abstract H-1013a.
8. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008; 83: 293-9.
9. Rhee EG, Rizk ML, Brainard DM, et al. A pharmacokinetic comparison of adult and pediatric formulations of raltegravir in healthy adults. Antivir Ther 2014; 19:619-24.
10. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-54.
11. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50: 605-12.